Morgan Stanley Raises Biogen Price Target to $200
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy BIIB?
Morgan Stanley raised the firm's price target on Biogen to $200 from $190 and keeps an Equal Weight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 177.110
Low
143.00
Averages
204.45
High
246.00
Current: 177.110
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Morgan Stanley Raises Biogen Price Target to $200
- Price Target Adjustment: Morgan Stanley raised Biogen's price target from $190 to $200 while maintaining an Equal Weight rating, reflecting a cautiously optimistic outlook on the company's future performance.
- Model Updates: The firm adjusted its models across its biopharma coverage to reflect IQVIA trends and intra-quarter updates, demonstrating keen insights into industry dynamics.
- Competitive Analysis: RBC Capital lowered Biogen's price target to $213, while H.C. Wainwright raised it to $237, indicating differing market perspectives on Biogen's outlook, which could impact investor confidence.
- Financial Expectations: Biogen anticipates that its Q1 results will include a $34 million expense on a pre-tax basis, which may exert pressure on its short-term stock performance, prompting investors to closely monitor the actual results in the upcoming earnings report.
See More
A Doctor's Journey with His Son's Rare Disease
- Family Life Restructured: Dr. Joseph D'Orazio's family life was immediately altered upon learning of his son Gabe's diagnosis of Angelman syndrome, necessitating a complete reevaluation of daily routines and future plans to accommodate the realities of a special needs family.
- Emotional and Professional Intertwining: As a physician, facing his son's rare disease brought profound grief and a sense of loss of control, which transformed his emotional landscape and deepened his empathy and understanding for patients' suffering in his medical career.
- Patience and Growth: Gabe's condition taught Dr. D'Orazio invaluable lessons in patience and a reevaluation of life, enhancing his focus on emotional needs in medical practice and significantly improving his empathy as a physician.
- Community and Advocacy: By engaging with the Foundation for Angelman Syndrome Therapeutics, Dr. D'Orazio transformed feelings of isolation into connection, aiding other families and advancing research, showcasing the resilience and unity of families affected by rare diseases.
See More
ALLOY: BIOGEN TO UTILIZE PLATFORM IN COLLABORATION TO FURTHER ANTISENSE THERAPEUTICS FOR SEVERAL UNDISCLOSED TARGETS
- Collaboration Focus: BioGen is collaborating to enhance the application of its platform in advancing anti-sense therapeutics.
- Targeting Strategy: The collaboration aims to address multiple undisclosed targets in the therapeutic landscape.
See More
ALLOY THERAPEUTICS ANNOUNCES MULTI-TARGET COLLABORATION AND LICENSE DEAL WITH BIOGEN FOR ALLOY'S ANTICLASTIC™ ASO PLATFORM
Collaboration Announcement: Alloy Therapeutics has entered into a multi-target collaboration and licensing agreement with Biogen.
Platform Utilization: The agreement allows Biogen to utilize Alloy's Anticlastics™ platform for their research and development efforts.
See More
Biogen Plans $34 Million Charge Impacting Q1 Earnings
- Stock Market Decline: Biogen's stock fell nearly 3% on Monday after the company announced plans to book a $34 million charge in Q1, indicating investor concerns about its financial health.
- Expense Breakdown: The charge consists of in-process R&D costs and milestone payments, expected to reduce net income by approximately $0.19 per share, directly impacting investor confidence.
- Earnings Release Schedule: Biogen has scheduled its Q1 earnings report for April 29 before market open, with initial expectations of a slight year-over-year gain to $2.95 per share now at risk due to the newly announced charge.
- Acquisition Activity: Recently, Biogen announced a $5.6 billion acquisition of Apellis Pharmaceuticals, which has also unsettled investors; however, the company is pivoting from its traditional focus on multiple sclerosis therapies to higher-potential market segments.
See More
Biogen Plans to Book $34 Million Charge in Q1
- Charge Impact: Biogen plans to book a $34 million charge in Q1, which will directly affect its net income, with an expected loss of approximately $0.19 per share, indicating increased spending on R&D and milestone payments.
- Market Reaction: Following this announcement, Biogen's stock fell nearly 3%, reflecting investor concerns about the company's future profitability, especially as it faces pressure to pivot from its traditional multiple sclerosis therapies.
- Earnings Release Schedule: Biogen has scheduled its earnings report for April 29 before market open, with investors initially expecting a slight year-over-year increase in net income to $2.95 per share, but the $34 million charge may alter these expectations.
- Acquisition Activity: In recent weeks, Biogen announced its acquisition of Apellis Pharmaceuticals for approximately $5.6 billion, which, despite failing to boost stock prices, demonstrates the company's commitment to transitioning into higher-potential segments.
See More
Morgan Stanley Raises Biogen Price Target to $200
- Price Target Adjustment: Morgan Stanley raised Biogen's price target from $190 to $200 while maintaining an Equal Weight rating, reflecting a cautiously optimistic outlook on the company's future performance.
- Model Updates: The firm adjusted its models across its biopharma coverage to reflect IQVIA trends and intra-quarter updates, demonstrating keen insights into industry dynamics.
- Competitive Analysis: RBC Capital lowered Biogen's price target to $213, while H.C. Wainwright raised it to $237, indicating differing market perspectives on Biogen's outlook, which could impact investor confidence.
- Financial Expectations: Biogen anticipates that its Q1 results will include a $34 million expense on a pre-tax basis, which may exert pressure on its short-term stock performance, prompting investors to closely monitor the actual results in the upcoming earnings report.
See More
A Doctor's Journey with His Son's Rare Disease
- Family Life Restructured: Dr. Joseph D'Orazio's family life was immediately altered upon learning of his son Gabe's diagnosis of Angelman syndrome, necessitating a complete reevaluation of daily routines and future plans to accommodate the realities of a special needs family.
- Emotional and Professional Intertwining: As a physician, facing his son's rare disease brought profound grief and a sense of loss of control, which transformed his emotional landscape and deepened his empathy and understanding for patients' suffering in his medical career.
- Patience and Growth: Gabe's condition taught Dr. D'Orazio invaluable lessons in patience and a reevaluation of life, enhancing his focus on emotional needs in medical practice and significantly improving his empathy as a physician.
- Community and Advocacy: By engaging with the Foundation for Angelman Syndrome Therapeutics, Dr. D'Orazio transformed feelings of isolation into connection, aiding other families and advancing research, showcasing the resilience and unity of families affected by rare diseases.
See More
ALLOY: BIOGEN TO UTILIZE PLATFORM IN COLLABORATION TO FURTHER ANTISENSE THERAPEUTICS FOR SEVERAL UNDISCLOSED TARGETS
- Collaboration Focus: BioGen is collaborating to enhance the application of its platform in advancing anti-sense therapeutics.
- Targeting Strategy: The collaboration aims to address multiple undisclosed targets in the therapeutic landscape.
See More
ALLOY THERAPEUTICS ANNOUNCES MULTI-TARGET COLLABORATION AND LICENSE DEAL WITH BIOGEN FOR ALLOY'S ANTICLASTIC™ ASO PLATFORM
Collaboration Announcement: Alloy Therapeutics has entered into a multi-target collaboration and licensing agreement with Biogen.
Platform Utilization: The agreement allows Biogen to utilize Alloy's Anticlastics™ platform for their research and development efforts.
See More
Biogen Plans $34 Million Charge Impacting Q1 Earnings
- Stock Market Decline: Biogen's stock fell nearly 3% on Monday after the company announced plans to book a $34 million charge in Q1, indicating investor concerns about its financial health.
- Expense Breakdown: The charge consists of in-process R&D costs and milestone payments, expected to reduce net income by approximately $0.19 per share, directly impacting investor confidence.
- Earnings Release Schedule: Biogen has scheduled its Q1 earnings report for April 29 before market open, with initial expectations of a slight year-over-year gain to $2.95 per share now at risk due to the newly announced charge.
- Acquisition Activity: Recently, Biogen announced a $5.6 billion acquisition of Apellis Pharmaceuticals, which has also unsettled investors; however, the company is pivoting from its traditional focus on multiple sclerosis therapies to higher-potential market segments.
See More
Biogen Plans to Book $34 Million Charge in Q1
- Charge Impact: Biogen plans to book a $34 million charge in Q1, which will directly affect its net income, with an expected loss of approximately $0.19 per share, indicating increased spending on R&D and milestone payments.
- Market Reaction: Following this announcement, Biogen's stock fell nearly 3%, reflecting investor concerns about the company's future profitability, especially as it faces pressure to pivot from its traditional multiple sclerosis therapies.
- Earnings Release Schedule: Biogen has scheduled its earnings report for April 29 before market open, with investors initially expecting a slight year-over-year increase in net income to $2.95 per share, but the $34 million charge may alter these expectations.
- Acquisition Activity: In recent weeks, Biogen announced its acquisition of Apellis Pharmaceuticals for approximately $5.6 billion, which, despite failing to boost stock prices, demonstrates the company's commitment to transitioning into higher-potential segments.
See More
